The Mounjaro questions most people have but aren't sure where to ask

You've seen the headlines — but does it actually work the way they claim?

Imagine reading that a weekly injection can reduce body weight by around a fifth. It sounds like the sort of number that belongs in a supplement ad, not a peer-reviewed journal. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, adults using tirzepatide at the highest dose lost an average of around 20–21% of their body weight over 72 weeks, alongside a reduced-calorie diet and increased activity. That figure comes from 2,539 participants, a substantial, well-designed study, not a small pilot.

The mechanism matters here. Mounjaro works on two receptors: GIP and GLP-1. Both are involved in appetite signalling and blood-sugar regulation. Activating both pathways at once is what distinguishes tirzepatide from older GLP-1 medicines, and the science behind tirzepatide is increasingly well understood. Slower gastric emptying means food sits in the stomach longer; the brain receives fewer hunger signals. For most people that doesn't feel like white-knuckling through appetite, it feels, oddly, like having a smaller appetite to begin with.

That said, results in clinical trials are averages. Individual responses vary, and a prescriber will set realistic expectations at your consultation, not a guaranteed outcome. The evidence is genuinely strong; the marketing around it sometimes overshoots even that.

What Mounjaro questions come up around side effects, and which ones need urgent attention?

The honest answer is that most people notice something in the first few weeks, particularly around the stomach. Nausea is the most reported effect, followed by loose stools, constipation, burping, and a feeling of fullness that tips into discomfort if you eat too fast or too much at once. These tend to be worst in the days after starting or after a dose increase, then settle. Eating smaller portions, avoiding high-fat meals, and staying hydrated makes a practical difference, something the NHS tirzepatide page covers in straightforward detail.

A smaller number of people experience more persistent indigestion, which is worth discussing with a prescriber rather than pushing through. The symptom that requires urgent medical help is different in character: severe stomach pain that radiates towards the back, with or without vomiting, can be a sign of acute pancreatitis. This is an infrequent but serious effect; the MHRA issued a Drug Safety Update on GLP-1 medicines in January 2026 specifically highlighting it. If that kind of pain develops, stop and seek medical assessment that day.

Allergic reactions are rare but possible. Injection-site redness or itching is more common and usually brief. Rotate sites (abdomen, thigh, upper arm) to reduce local reactions.

The eligibility questions: who does this apply to, and how does a UK prescriber decide?

The licensed criteria for private prescription are: adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. Those are the starting parameters; a prescriber then looks at the whole picture.

A full clinical assessment includes health history, any medicines you already take, and whether contraindications apply. Mounjaro isn't recommended during pregnancy, while breastfeeding, or when actively trying to conceive. It isn't licensed for under-18s. A history of medullary thyroid cancer or MEN2 syndrome means it can't be used. Women taking oral contraceptives need to add a non-oral contraceptive method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying can reduce pill absorption, something easy to miss in the general coverage.

If you want to understand the full indications for Mounjaro in the UK, that page sets them out alongside the NICE criteria for NHS access. Private and NHS routes have different thresholds, and it's worth knowing which applies to your situation before your consultation.

Practical questions: what actually happens when you start?

The first pen contains 2.5 mg, a dose chosen because it lets your body adjust before any therapeutic effect is expected. Most people won't notice dramatic changes at that stage, which is intentional. The titration from there is guided by your prescriber based on how you're tolerating the medicine, not a rigid calendar.

On the logistics side: the pen lives in the fridge between uses (2–8°C), and there's a limited window for room-temperature storage if you're travelling, the exact timeframe is in the Patient Information Leaflet and varies by product, so check that rather than relying on general advice online. Each pen delivers four weekly doses via a short subcutaneous injection. The directions for using Mounjaro cover the injection technique in full.

For the initial assessment itself, it helps to have a clear record of your current weight, any relevant diagnoses, and the medicines you take. If you're considering starting, the clinical questionnaire gives you a sense of what a prescriber will want to know. You can also browse the treatment options at nume before committing to anything, there's no charge for the consultation and no obligation to proceed. Understanding the full picture of what Mounjaro involves before your first pen arrives is, frankly, the best preparation. Separately, if questions about cost keep coming up, the weight-loss overview page puts the price context in one place.

A prescriber at a GPhC-registered pharmacy reviews every consultation personally, order before 12pm on a working day and, if clinically approved, your treatment is dispatched the same afternoon. Check your eligibility by starting a free consultation with our clinical team.